A type of HPV can cause skin cancer in people with weakened immune systems, report finds
The culprit is a type of human papillomavirus (HPV) that's regularly found on the skin. It's long been thought to play a role in the development of skin cancer, but wasn't believed to be a direct cause.
Skin cancer is caused by DNA damage in skin cells. The most common source of that damage is ultraviolet radiation from the sun. HPV can help UV-damaged DNA build up in cells and turn cancerous. However, in the new case report, doctors found that the virus itself could cause cancerous lesions to form.
The discovery was made in a 34-year-old woman with a weakened immune system; experts said it's highly unlikely that HPV could play the same role in causing skin cancer in a person with a healthy immune system.
'The virus replicated in a somewhat uncontrolled manner and ended up integrating into the skin cells and once they did that, they became cancerous,' said Dr. Andrea Lisco, section chief of the mucosal and cutaneous viral immunopathogenesis unit at the National Institute of Allergy and Infectious Diseases, part of the NIH. Lisco was the woman's doctor and also the senior author of the case report.
The woman had 43 spots of cutaneous squamous cell carcinoma — the second-most common type of skin cancer, after melanoma — on her face, hands and legs. She had surgery to remove the cancers and immunotherapy, but the cancer returned. When Lisco and his team biopsied several of her new tumors, they found that the woman's skin cancer was being driven by something they hadn't seen before: a group of HPVs called beta HPV.
About 90% of people carry a strain of beta HPV. Usually, the virus lives on the skin and doesn't integrate into the DNA of skin cells.
'We shake hands and we pick up those viruses, but if our immune systems are under control, we are fine,' Lisco said.
It's a different group of HPV strains — alpha HPVs — that are linked to a range of cancers. Alpha HPVs live on mucus membranes and can integrate into DNA, causing cancers of the cervix, anus, head and neck.
The woman in the case report had a genetic condition that weakened her T-cells (a type of immune cell), leaving her immunocompromised. This allowed the beta HPV living on her skin to behave more like alpha HPV, integrating its DNA into her skin cells and replicating undisturbed, turning the cells cancerous.
'You don't know how much you can directly apply the information from one patient to the wide variety of patients,' said Dr. Anthony Oro, professor of dermatology at Stanford Medicine, who wasn't involved in the case.
However, 'it suggests that, in the event that the T-cell arm of the immune system is not doing its job, beta-type HPV viruses could contribute to skin cancer, and maybe other kinds of cancers as well,' he said.
The patient needed a stem cell transplant, which replaced her defective T-cells with T-cells that could prevent the HPV from replicating.
'We needed to give this patient a whole new immune system,' Lisco said. It worked. Three years post-transplant, the woman's skin cancer has not returned.
'It gives us good information about how the interplay of the HPV and the immune system works,' said Dr. Anthony Rossi, a dermatologist and Mohs surgeon at Memorial Sloan Kettering Cancer Center, who also wasn't involved with the woman's case.
Doctors have known for a long time that some beta HPVs cause changes on the skin, such as warts on the hands and feet.
'HPV can integrate and cause changes in the cell cycle, especially in people with suppressed immune systems,' Rossi said. 'What was novel about this is that they found out it was a beta HPV that integrated into the DNA.'
Other researchers have speculated this was a possibility based on studies in mice, but the new report shows that it can occur in humans. How many people could be at risk is still unknown.
'This is just one patient, and they have this unique situation of an immunological condition that enables the beta HPV to replicate unchecked,' Oro said.
Other biopsies of squamous skin cancers have not detected HPV, meaning not all cases are caused by the viruses. Lisco said that the original notion — that HPV passively contributes to cutaneous squamous cell carcinoma by helping UV radiation damage skin cells, but doesn't actively help cancer grow — is still the likely explanation for many people.
For them, 'protection from UV would be the prevention,' Lisco said — wearing sunscreen and covering up your skin from the sun — adding that immunocompromised people should be monitored more closely. People with weakened immune systems are as much as 100 times more likely to develop squamous cell carcinoma.
The Gardasil HPV vaccine protects against nine strains of alpha HPV and has been shown to lower rates of cervical and head and neck cancers. It's unclear how much cross-protection, if any, the vaccine provides against other strains of HPV, including beta HPV.
'Even if this strain is not in the vaccine, there is some theory that there is cross-talk between HPV strains,' Rossi said.
Most people will get HPV in their lifetimes. Scientists have so far identified about 200 unique strains of the virus. Alpha-HPV, with its well-established links to cancer, has thus far been the primary subject of research.
'This suggests that this other side of the family might also be important in situations where our immune system is not doing its job,' Oro said.
This article was originally published on NBCNews.com
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Is There Really About to Be a Breast Cancer Vaccine?
For decades, the idea of a vaccine that could prevent breast cancer has felt more like science fiction than science. But recently, headlines touting 'breakthroughs' and 'game-changers' have sparked a new wave of hope and some skepticism. Could we really be on the cusp of immunizing against one of the most common and deadly cancers affecting women worldwide? Behind the buzz are early-stage clinical trials, promising preliminary results and a growing understanding of how the immune system can be trained to recognize and attack cancer cells. As researchers push forward, the science behind these potential vaccines—and what they might mean for the future of cancer prevention—is becoming increasingly compelling. More from Flow Space New Nimbus & Stratus COVID Variants Are Spreading-Here's Why Midlife Women Should Be Concerned How a Breast Cancer Vaccine Could Work and What Makes It Different A breast cancer vaccine is a type of immunotherapy designed to prevent, treat or reduce the risk of breast cancer recurrence by training the body's immune system to recognize and attack cancer cells. There are two main types under development. Preventive (Prophylactic) Vaccines:These are meant to stop cancer before it starts—similar to how traditional vaccines prevent infectious diseases like measles or HPV. For breast cancer, preventive vaccines are still experimental and are generally being tested on people who are considered high risk (like those with BRCA mutations or a strong family history). Therapeutic Vaccines:These are designed for people who already have breast cancer or have completed treatment but are at risk of recurrence. The goal is to boost the immune response against cancer-specific markers (like HER2 or mammaglobin-A), so the body can find and destroy any remaining cancer cells. 'Unlike traditional vaccines for infectious diseases (such as flu or COVID-19), which prevent infections caused by external pathogens, breast cancer vaccines target abnormal cellular changes to either prevent cancer or treat it by reducing recurrence,' Dr. Marie Ward, regional director of breast surgery at NYC Health + Hospitals's Jacobi Medical Center, tells Flow Space. By exposing the immune system to these antigens, the vaccine helps it 'learn' what cancer cells look like, so it can mount a stronger, more targeted attack. Where Does the Research Stand? While no breast cancer vaccine is currently approved for widespread use, several promising vaccine candidates are in clinical trials, targeting different approaches to breast cancer, including primary prevention and recurrence prevention. As of mid-2025, Ward says there are at least 15 breast cancer vaccine clinical trials in various stages in the U.S., some in phase II and III. She says some notable examples include: NeuVax (targets Her2): advanced trials mRNA vaccines (e.g., MUC1-based) show promising early results in disease-free survival (DFS) and reduction of recurrence Alpha-lactalbumin vaccines for triple-negative breast cancer One of the most closely watched efforts is being led by the Cleveland Clinic, which launched its phase I trial of a preventive breast cancer vaccine in 2021. 'This vaccine targets α-lactalbumin—a protein normally produced only during lactation but abnormally expressed in many triple-negative breast cancers—a particularly aggressive and hard-to-treat subtype,' Dr. Brooke Davis, breast medical oncologist at Oncology Specialists of Charlotte in North Carolina, tells Flow Space. The trial is testing the vaccine in women who are currently cancer-free but considered high-risk due to genetic mutations (like BRCA1/2) or family history. The current focus is on evaluating safety, immune response and tolerability. If early results are promising, the study will expand to larger groups and later-phase trials to assess long-term protection Meanwhile, therapeutic vaccines are also advancing. These vaccines don't aim to prevent the disease from occurring, but rather to help the immune system better identify and destroy cancer cells, especially those that may linger after treatment and cause recurrence. For instance, researchers are developing HER2-targeted vaccines, which are designed to activate immune cells against breast cancers that overexpress the HER2 protein. 'These are currently being studied in combination with other treatments, such as checkpoint inhibitors, in hopes of amplifying their effectiveness,' adds Davis. Additionally, mRNA vaccine technology is being adapted for breast cancer applications. Companies like BioNTech and Moderna, which were instrumental in developing COVID-19 vaccines, are now exploring whether personalized mRNA vaccines can teach the immune system to target tumor-specific neoantigens—essentially custom-building a vaccine unique to each patient's cancer. Early results across multiple trials have shown that these vaccines are capable of producing measurable immune responses and appear to be safe, with relatively mild side effects. However, most studies are still in phase I or phase II, meaning it's too soon to know whether they will lead to significant reductions in cancer risk or recurrence. That said, both interest and investment in this space are growing rapidly. The National Cancer Institute and the Department of Defense are funding numerous breast cancer vaccine studies, reflecting growing institutional confidence in the field. Epidemiologist Dr. Scarlett Lin Gomez, co-leader of the Cancer Control Program at University of Central South Florida who specializes in studying breast cancer rates among Asian-American women is currently conducting the CRANE study. Its goal is to understand the risk factors underlying the high and increasing rates of breast cancer in Asian American females. 'But in a more general sense, raising awareness among the medical community about the severity of breast cancer and its rising cases within minority groups only sheds light on how much a vaccine would be a game changer,' she notes. However, researchers caution that a universal breast cancer vaccine—one that could be given to the general population, much like the HPV vaccine—is likely still many years away, if it proves possible at all. 'The ideal future model combines both: a standard vaccine base with individualized components tailored to a patient's unique tumor biology,' explains Ward. What's Next? Every breast cancer vaccine trial underway today is doing more than just testing a single intervention; it's helping to define the future of cancer prevention and treatment. While we're still years away from routine, widespread vaccination against breast cancer, researchers are gathering critical insights that are shaping the next generation of cancer vaccines. Ward says one of the major milestones the field is working toward is the successful demonstration of reduced recurrence or prevention rates in large, randomized phase III trials, which could lead to regulatory approval, particularly for high-risk populations. But reaching that point, she emphasizes, requires a more sophisticated approach than a vaccine alone. 'One of our key learnings is that vaccines are far more effective when combined with other forms of immunotherapy, such as checkpoint inhibitors,' Ward explains. 'Cancer is expert at evading immune recognition. You need to unmask it—and that often takes multiple tools working in tandem.' Another essential insight has come from understanding which antigens best trigger a protective immune response. 'We're learning to distinguish between shared antigens, which are common across many tumors, and personalized neoantigens, which are unique to each patient's cancer,' says Ward. 'Both have potential, but personalizing the immune response could offer stronger, longer-lasting protection.' Technological innovation is playing a major role in shaping these next-generation vaccines, as well, adds Davis. She says that with mRNA platforms and machine learning, scientists are able to design and adapt vaccines more rapidly than ever before, and these tools allow us to evolve the vaccine alongside the tumor, which is critical because cancer isn't static, it changes. At the same time, researchers are gaining a better understanding of why some vaccines underperform. One of the most promising avenues for current vaccines is minimal residual disease settings—after the primary tumor has been removed or treated, but before the cancer has a chance to come back. In these scenarios, the tumor burden is low, and the immune system has a better shot at clearing out any remaining cells. Ultimately, experts agree that breast cancer vaccines will more than likely be part of a larger therapeutic strategy rather than a standalone solution. 'We're likely to see vaccines used alongside existing therapies—chemotherapy, targeted drugs and immunotherapy—for a synergistic benefit,' Ward says. 'It's about boosting the immune system in a smarter, more targeted way. But the lessons we're learning now are invaluable. They're helping us build smarter, safer and more effective vaccines and bringing us closer to a future where cancer prevention is proactive, not reactive.' Solve the daily Crossword
New York Post
4 hours ago
- New York Post
Stop obsessing over protein goals — the latest health craze — and just enjoy your food
The cookbook section of any used bookstore is a museum of past health trends. Browse through the stock and you'll trace the rise and fall of nutritional villains: eggs, butter, red meat and more — first demonized, then rehabilitated by the next wave of experts. We've all seen America's food rules shift beneath our feet, as nutritional gospel one year becomes heresy the next. In 2025, we're in the era of protein. More specifically, we're in the era of more protein. Advertisement Inspired by bodybuilders, weight-lifters and hardcore health gurus, packing on the protein has gone mainstream. But while these athletes need the nutrient to build muscle and maintain their exercise routines, the average carpooling mom has no such requirement. Yet grocery-store shelves shout their macronutrient stats like badges of honor: '18 grams per serving!' 'Protein-rich!' Advertisement Social-media influencers cheerfully explain how to sneak ever more protein into cookies, pancakes and even ice cream; cottage cheese is the new star of the show, blended into everything from pasta sauce to dessert bars. Ads hawk 'gourmet protein powders' to be dumped into your morning latte. Many women's Instagram feeds have become a stream of 'high-protein lunchbox' reels and 'six ways to eat 100g of protein' posts. Advertisement I recently watched as one food blogger, a former champion of plant-based eating, crammed half a rotisserie chicken into her mouth on camera. Her caption: 'Gotta hit those protein goals!' Curious about my own goals, I calculated how much protein I'd need to eat in a day to meet the online experts' frequently cited benchmarks. The result was nauseating: seven eggs for breakfast, a whole chicken breast for lunch, meat again for dinner, plus multiple high-protein snacks — Greek yogurt, nuts, cottage cheese, protein bars — to stay on target. This isn't just a quirky health trend. It's disordered eating with a veneer of wellness. Advertisement That's not to say protein is bad for you; quite the opposite. It's a vital macronutrient, essential for muscle repair, hormone production and immune function; it also provides a sense of fullness after meals, helping to maintain a healthy weight. For growing kids, pregnant women, aging adults and those recovering from illness or intense exercise, protein is especially crucial. The problem isn't the nutrient itself, but the obsessive, all-consuming fixation on it. Consider this: For a healthy, active 175-pound man, the National Institutes of Health recommends about 63 grams of protein per day. But the popular MyFitnessPal website advises that same man to aim for 164 grams, well more than double the federal guideline. 'The average man in the United States is overshooting the federal protein recommendation by more than 55%,' says Alice Callahan, a New York Times health reporter who holds a nutrition PhD, 'and the average woman by more than 35%.' What happens to all that extra protein? The body can't store it. Instead, the liver converts the surplus into energy — and if that isn't used, packs it on as fat. Advertisement So if we're already getting enough, why the obsession? Maybe it has something to do with who's leading the conversation. A 2017 study published in the Journal of the Academy of Nutrition and Dietetics found that 49.5% of registered dietitians were at risk for orthorexia nervosa, a condition marked by an unhealthy fixation on eating 'correctly.' Another 13% were at risk for traditional eating disorders like anorexia, and 8% had previously received treatment for them. Advertisement In other words, the very people we look to for food guidance may be struggling with disordered eating habits themselves. Women are more prone to eating disorders than men by orders of magnitude — and the current protein craze is largely female-led. Compared to other nutrition fads, the high-protein trend might seem harmless; after all, it's not demanding the total elimination of food groups, or promoting outright starvation. Advertisement However, it's steeped in the same obsessive mindset. When every bite must be justified by its protein content, when food becomes math instead of nourishment, something has gone wrong. A healthy approach to protein centers on real, unprocessed foods like eggs, fish, beans, nuts, meat and dairy — not processed powders with ingredients you can't pronounce, or bars that taste like compressed chalk. You don't need to count every gram or hit some arbitrary benchmark. Just eat a variety of whole foods, and you'll get what you need. Food fuels our bodies, but it's also meant to be enjoyed. We shouldn't have to choke down dry chicken or gag on cottage-cheese brownies in the name of health. Advertisement Because if wellness doesn't include balance, sanity and flexibility, it isn't wellness at all. Bethany Mandel writes and podcasts at The Mom Wars and is a homeschooling mother of six in greater Washington, DC.
NBC News
18 hours ago
- NBC News
UCLA says it is losing some federal research funding
The California university UCLA said Thursday that it has been notified that it is losing federal research funding over alleged antisemtism, a move the chancellor called "a loss for America." 'UCLA received a notice that the federal government, through its control of the National Science Foundation (NSF), the National Institutes of Health (NIH) and other agencies, is suspending certain research funding to UCLA,' university Chancellor Julio Frenk said in a message to the campus community. 'This is not only a loss to the researchers who rely on critical grants. It is a loss for Americans across the nation whose work, health, and future depend on the groundbreaking work we do,' he wrote. The announced notice comes as the Trump administration has sought to pressure or retaliate against universities across the country following student protests on college campuses about the war in Gaza. Some Republican members of Congress and others have called the protests and some of the conduct antisemitic. Frenk in his message to the UCLA community said that the federal government used antisemitism as its reason for the loss of funding. "In its notice to us, the federal government claims antisemitism and bias as the reasons. This far-reaching penalty of defunding life-saving research does nothing to address any alleged discrimination," he wrote. UCLA announced Tuesday that it has agreed to pay $6 million to settle a lawsuit that alleged discrimination, and which was brought by Jewish students and a faculty member. The lawsuit filed in June 2024 accused the university of failing to take action when pro-Palestinian protesters set up encampments on campus that spring. Frenk wrote in the message to the Bruin community — as the UCLA community is known — that antisemitism has no place on campus but acknowledged room for improvement. He said that the university has taken steps to combat it, and put in place policies about student protests. The National Science Foundation and the National Institutes of Health did not immediately respond to requests for comment late Thursday. Frenk in his message to the university did not say how much federal funding will be suspended. He highlighted important work done by UCLA, which included helping to create what would become the Internet, and he said researchers "are now building new technologies that could fuel entire industries and help safeguard our soldiers." President Donald Trump during his campaign pledged to crack down on universities because of student protests against the war in Gaza, which Israel launched against Hamas after the Hamas attacks on Oct. 7, 2023, that targeted Israeli civilians, including at a music festival. There is now a humanitarian crisis in Gaza, and this week t he United Nations said the U.N.'s Integrated Food Security Phase Classification, or IPC, showed mounting evidence of a worsening famine there. The IPC emphasized that its warning constituted an alert and was not a formal 'famine classification.' Columbia University in New York City was among the universities targeted by the Trump administration over allegations of antisemitism, and last week Columbia announced a settlement with the federal government in an effort to restore cut federal funding. Brown University in Rhode Island said Wednesday that it reached an agreement with the federal government to restore funding. The university said that agreement resolves three reviews of Brown's 'compliance with federal nondiscrimination obligations.'
